PMID- 25304928
OWN - NLM
STAT- MEDLINE
DCOM- 20150127
LR  - 20220408
IS  - 1365-229X (Electronic)
IS  - 0009-9260 (Linking)
VI  - 69
IP  - 12
DP  - 2014 Dec
TI  - Safety and efficacy of transarterial chemoembolization plus sorafenib for 
      hepatocellular carcinoma with portal venous tumour thrombus.
PG  - e553-61
LID - S0009-9260(14)00436-X [pii]
LID - 10.1016/j.crad.2014.09.007 [doi]
AB  - AIM: To evaluate the safety and efficacy of combined therapy with transarterial 
      chemoembolization (TACE) and sorafenib for hepatocellular carcinoma (HCC) with 
      portal venous tumour thrombus (PVTT). MATERIALS AND METHODS: This study was 
      approved by the institutional review board. From May 2009 to May 2012, 170 
      consecutive patients were newly diagnosed with advanced-stage HCC and treated 
      with TACE plus sorafenib. Among them, 41 patients with PVTT were retrospectively 
      enrolled in the study. The adverse events (AEs), overall survival (OS), time to 
      progression (TTP), and prognostic factors were analysed. Statistical analysis was 
      performed with the Kaplan-Meier method using the log-rank test and Cox regression 
      models. RESULTS: The most common AEs were hand-foot skin reaction related to 
      sorafenib and fever related to TACE. Procedure-related mortality and grade 4 AEs 
      were not observed. Grade 3 AEs were observed in five patients. During the median 
      follow-up period of 13.5 months (range 1.4-45 months), the 6-month and 1-year 
      survival rates were 87.7% and 53.6%, respectively. The median OS was 13 months 
      (range 1.4-44.8 months), and the median TTP was 7 months (range 1-18.6 months). 
      The Child-Pugh class (p = 0.022), extrahepatic metastasis (p = 0.009), and gross 
      morphological type (nodular type versus diffuse type; p = 0.008) were prognostic 
      factors related to OS in the multivariate analysis. CONCLUSION: TACE plus 
      sorafenib in an interrupted therapeutic scheme was well tolerated and might 
      improve OS for HCC patients with PVTT, especially in those with Child-Pugh class 
      A, no extrahepatic metastasis, or nodular-type HCC.
CI  - Copyright (c) 2014 The Royal College of Radiologists. Published by Elsevier Ltd. 
      All rights reserved.
FAU - Pan, T
AU  - Pan T
AD  - Minimally Invasive Interventional Division, Medical Imaging Center, State Key 
      Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China.
FAU - Li, X-S
AU  - Li XS
AD  - Department of Interventional Radiology, Guangzhou First People's Hospital, 
      Guangzhou Medical University, Guangzhou, PR China.
FAU - Xie, Q-K
AU  - Xie QK
AD  - Minimally Invasive Interventional Division, Medical Imaging Center, State Key 
      Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China.
FAU - Wang, J-P
AU  - Wang JP
AD  - Minimally Invasive Interventional and Target Treatment Division and Cancer 
      Center, The First People's Hospital of Foshan City, The Affiliated Foshan 
      Hospital of Sun Yat-sen University, Guangzhou, PR China.
FAU - Li, W
AU  - Li W
AD  - Minimally Invasive Interventional Division, Medical Imaging Center, State Key 
      Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China.
FAU - Wu, P-H
AU  - Wu PH
AD  - Minimally Invasive Interventional Division, Medical Imaging Center, State Key 
      Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China.
FAU - Zhao, M
AU  - Zhao M
AD  - Minimally Invasive Interventional Division, Medical Imaging Center, State Key 
      Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China. 
      Electronic address: zhaoming@sysucc.org.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141007
PL  - England
TA  - Clin Radiol
JT  - Clinical radiology
JID - 1306016
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Carcinoma, Hepatocellular/complications/drug therapy/*therapy
MH  - Chemoembolization, Therapeutic/adverse effects/*methods
MH  - Combined Modality Therapy/methods
MH  - Dermatitis/etiology
MH  - Diarrhea/etiology
MH  - Fatigue/etiology
MH  - Female
MH  - Fever/etiology
MH  - Follow-Up Studies
MH  - Humans
MH  - Liver Neoplasms/complications/drug therapy/*therapy
MH  - Male
MH  - Middle Aged
MH  - Niacinamide/adverse effects/*analogs & derivatives/therapeutic use
MH  - Phenylurea Compounds/adverse effects/*therapeutic use
MH  - Portal Vein/*pathology
MH  - Retrospective Studies
MH  - Sorafenib
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Venous Thrombosis/complications/drug therapy/*therapy
EDAT- 2014/10/12 06:00
MHDA- 2015/01/28 06:00
CRDT- 2014/10/12 06:00
PHST- 2014/05/19 00:00 [received]
PHST- 2014/08/15 00:00 [revised]
PHST- 2014/09/09 00:00 [accepted]
PHST- 2014/10/12 06:00 [entrez]
PHST- 2014/10/12 06:00 [pubmed]
PHST- 2015/01/28 06:00 [medline]
AID - S0009-9260(14)00436-X [pii]
AID - 10.1016/j.crad.2014.09.007 [doi]
PST - ppublish
SO  - Clin Radiol. 2014 Dec;69(12):e553-61. doi: 10.1016/j.crad.2014.09.007. Epub 2014 
      Oct 7.